Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145181 | 0.93 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP2C9KCNH2ALDH1A1 | |
| SCHEMBL3152053 | 0.92 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP2C9KCNH2PDE5A | |
| SCHEMBL3151835 | 0.88 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3151633 | 0.86 | CYP3A4 (0.41) | CYP3A4CYP2D6CYP2C9KCNH2MCHR1 | |
| SCHEMBL3145858 | 0.86 | CYP3A4 (0.40) | CYP3A4CYP2D6CYP2C9KCNH2LRRK2 | |
| SCHEMBL3164134 | 0.86 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3159602 | 0.83 | CYP3A4 (0.49) | CYP3A4CYP2D6CYP2C9KCNH2EGLN1 | |
| SCHEMBL13119805 | 0.83 | KCNH2 (0.48) | CYP3A4CYP2D6CYP2C9KCNH2EGLN1 | |
| SCHEMBL3151052 | 0.83 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP2C9KCNH2EGLN1 | |
| SCHEMBL13690733 | 0.81 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP2C9KCNH2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | claimed |
| EP-1910360-B1 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO INC (US) | 2010-03-03 | — | — | EP | claimed |
| EP-1912935-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | claimed |
| EP-1910360-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007015812-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | claimed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | claimed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1910360-B1 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1912935-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1910360-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015812-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | CYP3A4 862/4885CYP2D6 1726/4885CYP2C9 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.